What is a stock summary page? Click here for an overview.
Business Description
Maze Therapeutics Inc
NAICS : 541720
SIC : 2836
ISIN : US5787841007
Description
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 7.39 | |||||
| Equity-to-Asset | -1.29 | |||||
| Debt-to-Equity | -0.09 | |||||
| Debt-to-EBITDA | -0.51 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | -1.9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 42.56 | |||||
| 9-Day RSI | 42.53 | |||||
| 14-Day RSI | 41.27 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.76 | |||||
| Quick Ratio | 9.76 | |||||
| Cash Ratio | 9.52 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -3.18 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -2158.2 | |||||
| Net Margin % | -2173.24 | |||||
| FCF Margin % | -1854.6 | |||||
| ROA % | -30.17 | |||||
| ROIC % | -108.1 | |||||
| ROC (Joel Greenblatt) % | -168.61 | |||||
| ROCE % | -33.5 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 145.51 | |||||
| EV-to-EBIT | -3.1 | |||||
| EV-to-EBITDA | -3.18 | |||||
| EV-to-Revenue | 66.82 | |||||
| EV-to-FCF | -3.6 | |||||
| Earnings Yield (Greenblatt) % | -32.26 | |||||
| FCF Yield % | -12.89 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MAZE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Maze Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2.5 | ||
| EPS (TTM) ($) | -1.073 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 41.27 | ||
| 14-Day ATR ($) | 1.250792 | ||
| 20-Day SMA ($) | 8.931 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 6.71 - 17 | ||
| Shares Outstanding (Mil) | 43.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Maze Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Maze Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Maze Therapeutics Inc Frequently Asked Questions
What is Maze Therapeutics Inc(MAZE)'s stock price today?
The current price of MAZE is $8.21. The 52 week high of MAZE is $17.00 and 52 week low is $6.71.
When is next earnings date of Maze Therapeutics Inc(MAZE)?
The next earnings date of Maze Therapeutics Inc(MAZE) is 2025-05-30 Est..
Does Maze Therapeutics Inc(MAZE) pay dividends? If so, how much?
Maze Therapeutics Inc(MAZE) does not pay dividend.
Guru Commentaries on NAS:MAZE
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers